ODAC greenlights Novartis CAR-T cell the...Swiss Novartis is about to receive the very first market approval (BLA) for a CAR-T cell cancer therapy globally. The FDAs Oncologic Drugs Advisory Committee (ODAC) recommended approval of CTL019 (tisagenlecleucel) … more ➔
Enterome and Nestlé form JVFrench gut microbiome analysis specialist Enterome Bioscience SA and therapeutic nutrition company Nestlé Health Science have formed a 50:50 joint venture aimed at developing microbiome-based … more ➔
Bavaria and Germany push digital medicine As part of a €5bn investment by 2025, the Free State of Bavaria will kick off two ambitious digital medicine projects next year, government officials said at the Forum Science & Health.   … more ➔
FMI to launch digital oncology service at...At the opening ceremony for R&D, training and production buildings at Roche Penzberg, the Pharma giant said that Foundation Medicine (FMI) will establish a digital oncology service at the site offering … more ➔
Biocartis inks breast cancer R&D deal Belgian diagnostics company Biocartis Group NV and Singpores A*STAR ETPL have kicked off development of a multimodal breast cancer assay designed to guide therapy selection in personalised medici … more ➔
4SC AG raises €41m Small molecule cancer drug developer 4SC AG (Planegg-Martinsried, Germany) has completed a capital increase fueling development of its clinical programmes for resminostat, 4SC-202 and 4SC-208 more ➔
Success for individualised cancer vaccineGerman biotech company Biontech AG has published positive clinical results for its individualised cancer vaccine Ivac mutanome in patients with late-stage melanoma. more ➔
Seventure debuts in Japan with microbiome... Venture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventures Health for Life … more ➔
Noxxon/MSD start testing of immunoncologic...Last December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off … more ➔
Exscientia inks €37m contract with GSKBritish pharma giant GlaxoSmithKline has secured access to Ex Scientia Ltd (Exscientia)s artificial intelligence (AI)-driven drug discovery platform. more ➔
